Weight-loss supplements and weight-loss injections are often advertised alongside protein powders and commercial kits, but they are not the same type of product. They differ in evidence, regulation, medical purpose and the monitoring they require. A food licence does not turn a supplement into a medicine, and an injection used for diabetes is not automatically approved or appropriate for weight management.
This page explains categories, not products to choose. It gives no brands, doses or rankings. For diagnosis, Indian body mass index (BMI) cut-offs and the broader treatment pathway, begin with our weight management guide for Indians.
Weight-loss supplements and weight-loss injections are different categories
| Category | What it is | What the label or clinician should clarify |
|---|---|---|
| Health supplement or nutraceutical | A food-category product intended to supplement the usual diet or provide a physiological benefit | Ingredients, amounts, warnings, interactions and the statement that it is not for medicinal use |
| Meal replacement | A formulated food intended to replace one or more meals under its stated conditions | Whether it is a partial or full replacement, nutrients, intended group and medical-advice statement |
| Prescription obesity medicine | A medicine assessed for a defined indication and used with clinical follow-up | Why it is indicated, contraindications, side effects, interactions, monitoring and review plan |
Products within a commercial kit may fall into different rows. A shake can be a meal replacement, while a capsule or tea may be a supplement. Evidence for one component does not prove that the whole bundle improves health. Evaluate each label and claim separately.
What evidence says about weight-loss supplements
The United States National Institutes of Health Office of Dietary Supplements concludes that there is little scientific evidence that weight-loss supplements work. Studies are often small, short, or test combinations that make one ingredient difficult to judge. A small change on a scale is not the same as meaningful, sustained health improvement.
Stimulant and “fat burner” products
These may combine caffeine or stimulant-like botanicals and claim to increase metabolism or suppress appetite. Possible effects include palpitations, anxiety, poor sleep, raised blood pressure and medicine interactions. Combining several products can duplicate ingredients even when the front labels use different names.
Green tea extract, chromium and similar ingredients
Research has not established these as reliable long-term obesity treatments. Concentrated extracts can have risks that ordinary food or drink does not. “Natural” describes origin or marketing; it does not establish purity, a useful effect, or safety with heart, liver, blood-pressure or diabetes conditions.
Some internationally notified weight-loss products have contained undeclared medicines or other active substances. A regulator’s warning list can only identify products already tested; absence from a list does not prove that another product is safe.
Protein powder for weight loss: what it can and cannot do
Protein supports muscle and can improve fullness, but protein powder does not directly burn body fat. Weight changes when the overall eating pattern changes. Adding a shake on top of unchanged meals can add energy; replacing meals without enough fibre, vegetables and micronutrients can make the diet less complete.
The Indian Council of Medical Research–National Institute of Nutrition (ICMR-NIN) says protein supplements are unnecessary for normal healthy life and advises food combinations such as pulses with cereals, plus milk, eggs, fish or other preferred sources. It warns that prolonged large intakes of protein powders or high-protein concentrates may pose risks including kidney damage and bone-mineral loss.
Needs differ in illness, older age, sport and recovery. Kidney disease, a prescribed protein restriction, pregnancy or a history of disordered eating needs individual advice. See our high-protein vegetarian foods guide for ordinary Indian options.
How to read Indian commercial weight-management kits
Food Safety and Standards Authority of India (FSSAI) rules distinguish health supplements, nutraceuticals and Food for Special Dietary Use. A regulated meal replacement for weight control is a specific formulated-food category. It is not the same as an ordinary protein powder or a collection of supplements.
Check the legal category and full label
- Look for the category stated near the product name and the complete ingredient quantities.
- For a supplement or nutraceutical, check for “NOT FOR MEDICINAL USE,” recommended usage, warnings, contraindications and published interactions.
- For Food for Special Dietary Use, check the intended group, rationale, whether medical advice is stated, and whether it replaces part or all of the daily diet.
What a licence does not establish
Food-business licensing and compliance address the applicable food rules. They do not show that a kit produces greater or more durable weight loss than an ordinary balanced eating plan. Testimonials, before-and-after photographs and a long ingredient list are not controlled clinical evidence.
Prescription obesity medicines: the main types
Prescription obesity medicines act through defined biological pathways and are used alongside nutrition, physical activity and behavioural care. Indian guidance discusses oral medicines such as orlistat and certain appetite-regulating combinations, glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, and the glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist tirzepatide.
Orlistat
Orlistat reduces absorption of some dietary fat. Gastrointestinal effects can include oily stools, urgency and leakage, and absorption of fat-soluble vitamins or some medicines can be affected. It is contraindicated in pregnancy, chronic malabsorption and cholestasis.
GLP-1 medicines and the GIP/GLP-1 medicine
These medicines influence appetite, fullness and stomach emptying; some also treat type 2 diabetes under separate indications. Liraglutide, semaglutide and tirzepatide are not interchangeable labels. Formulation, indication and regulatory status matter. A medicine prescribed for diabetes should not be repurposed by the patient for weight loss.
Other prescription tablets
Indian clinical guidance also covers naltrexone/bupropion and phentermine/topiramate. Their suitability depends heavily on blood pressure, seizure risk, opioid use, mood, pregnancy potential, glaucoma, thyroid disease and interacting medicines. Listing them is not a recommendation.
Who may be assessed for prescription obesity medicines?
Eligibility is not decided from appearance or an online calculator alone. A clinician reviews Indian BMI and waist cut-offs, obesity-related conditions, functional effects, previous care, medicines, mental health, pregnancy plans and the likely balance of benefit and harm.
The Endocrine Society of India’s 2025 guidance uses lower India-specific thresholds than many international sources and considers comorbidities. The World Health Organization’s 2025 guideline conditionally supports long-term GLP-1 or GIP/GLP-1 therapy for adults with obesity as it defines it, excluding pregnant women, with behavioural support and monitoring. These frameworks have different scopes and should not be mixed into a self-prescribing rule.
Weight management is chronic care. Response varies, side effects can limit treatment, and weight regain after stopping is common in withdrawal studies. A review plan should cover health outcomes, tolerability and what happens if treatment is interrupted or stopped—not only the scale.
Side effects, contraindications and monitoring
Digestive and gallbladder effects
Nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reflux can occur with GLP-1-based medicines. Persistent severe abdominal pain, especially with vomiting or pain reaching the back, needs urgent assessment for pancreatitis. Right-upper abdominal pain, fever or jaundice can signal gallbladder disease.
Thyroid, stomach and allergy warnings
Current prescribing information for liraglutide, semaglutide and tirzepatide contraindicates use with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a previous serious hypersensitivity reaction to the medicine. Severe gastroparesis requires particular caution; some labels do not recommend use.
Diabetes medicines, dehydration and procedures
Using these medicines with insulin or an insulin-secretagogue can increase low-sugar risk. Repeated vomiting or diarrhoea can cause dehydration and kidney injury. Tell the clinical team before surgery, anaesthesia or deep sedation because delayed stomach emptying can affect procedure safety.
Pregnancy and breastfeeding: weight-loss medicines should not be used for weight reduction during pregnancy. Tell the prescriber before trying to conceive and as soon as pregnancy is recognised. Semaglutide prescribing information advises stopping at least 2 months before a planned pregnancy because it remains in the body for a long time. Do not stop or restart any medicine without the treating clinician’s plan.
Unverified products and unsafe combinations
Do not treat an unlabelled injection, a supplement with hidden ingredients or a mixture of several appetite products as equivalent to supervised treatment. Product identity, approved indication, storage history and sterility cannot be inferred from appearance. This article does not provide sourcing instructions.
Do not combine a supplement, meal-replacement programme and prescription medicine without showing the full labels and medicine list to the prescriber. Overlap can increase stimulant exposure, low sugar, dehydration, gastrointestinal effects or interactions.
When to see a doctor
Get emergency help
- Face or throat swelling, breathing difficulty, collapse or another severe allergic reaction.
- Confusion, seizure or unconsciousness from suspected low blood sugar.
- Severe persistent abdominal pain with vomiting, chest pain, severe breathlessness or fainting. In India, call 112.
Arrange prompt medical review
- Repeated vomiting, inability to keep fluids down, very little urine or marked dizziness.
- Right-upper abdominal pain, fever, jaundice, or severe constipation with swelling and vomiting.
- Repeated low-sugar episodes, palpitations, pregnancy recognised during treatment, or mood changes and thoughts of self-harm.
How Disha can help
Disha is an artificial intelligence (AI) health coach that chats and calls in Hindi, English and Hinglish. It can support food, movement and sleep routines around a plan made with your clinician. It does not select obesity treatment, assess side effects, prescribe, change medicines or provide emergency care. See how Disha coaching works.
The BMI calculator with Indian cut-offs is one screening tool, not a test of whether a medicine is suitable.
This is not medical advice. This page is general education for adults aged 18 and over. It does not recommend a supplement, kit or medicine. Do not start, combine, stop or change treatment because of it. A qualified clinician must assess contraindications, interactions, pregnancy plans and monitoring. In an emergency, call 112.
Frequently asked questions
Do weight-loss supplements work?
Most have little evidence of meaningful, lasting weight loss. Studies may be short, small or test mixtures that make each ingredient difficult to judge. Supplements can also interact with medicines or contain undeclared substances. A food-category label should not be interpreted as proof that the product treats obesity.
Are fat burners safe?
Safety depends on every ingredient, amount, combination, medical condition and medicine you take. Stimulant-like products can affect heart rate, blood pressure, anxiety and sleep. Some notified products have contained undeclared active substances. Discuss the full label with a clinician, especially with heart, liver, blood-pressure or diabetes conditions.
Does protein powder cause weight loss?
No powder directly burns fat. Protein may improve fullness and support muscle, but adding a shake can also add energy. ICMR-NIN recommends meeting needs through food for normal healthy life. Kidney disease, prescribed protein restriction, pregnancy and illness are reasons to obtain individual nutrition advice before increasing protein.
Does an FSSAI licence prove a commercial kit works?
No. FSSAI rules establish food categories, composition and labelling requirements. They do not prove that a particular kit causes durable weight loss or is suitable for you. Check each component separately because one bundle may contain a meal replacement, supplement and other products governed by different requirements.
Is a weight-loss injection the same as a diabetes injection?
Not automatically. Some active medicines have separate diabetes and obesity indications, formulations or labels. A diabetes prescription does not establish that the same product is suitable for weight management. The clinician must confirm the exact medicine, indication, contraindications and monitoring plan. Never repurpose or share an injection.
What happens when a weight-loss injection is stopped?
Appetite and weight can rise again, and withdrawal studies show regain is common. The amount varies. Obesity care therefore needs a long-term plan covering food, movement, sleep, medical conditions and follow-up. Do not stop suddenly because of side effects or supply interruption without contacting the treating clinician.
Can a weight-loss injection be used in pregnancy?
No weight-loss medicine should be used for weight reduction during pregnancy. Tell the prescriber if pregnancy is possible or planned. Semaglutide information advises stopping at least 2 months before planned pregnancy. If pregnancy is recognised during treatment, contact the prescriber promptly rather than making an unsupported restart plan later.
Sources
- Indian Council of Medical Research–National Institute of Nutrition. Dietary Guidelines for Indians. 2024. Supports food-first protein guidance and cautions about prolonged large protein-powder intake.
- National Institutes of Health Office of Dietary Supplements. Dietary Supplements for Weight Loss. Supports limited effectiveness evidence, interactions and undeclared-ingredient concerns.
- Food Safety and Standards Authority of India. Health Supplements and Nutraceutical Regulations. 2022. Supports Indian categories, label statements, warnings and interaction information.
- Endocrine Society of India. Clinical Practice Guidelines for the Evaluation and Management of Obesity in India. 2025. Supports India-specific assessment, medicine classes, adverse effects and contraindications.
- World Health Organization. Guideline on GLP-1 therapies for obesity. 2025. Supports conditional long-term use, exclusion of pregnancy, behavioural support and monitoring.
- United States Food and Drug Administration. Semaglutide prescribing information. 2025. Supports contraindications, warnings, procedure and pregnancy precautions.
- United States Food and Drug Administration. Tirzepatide prescribing information. 2026. Supports current contraindications and safety warnings.
Related reads
- Weight management in India: assessment, tests and treatment pathways.
- Indian diet plan for weight loss: a food-first plate using familiar meals.
- High-protein vegetarian foods: practical alternatives to routine powder use.
- Diabetes medicines explained: how GLP-1 medicines differ from insulin.
- All weight-management articles: browse the complete collection.
